NRx Launches Defense Subsidiary for Robotic TMS and D-Cycloserine PTSD Therapy
NRx Pharmaceuticals incorporated NRx Defense Systems, led by Dr. Dennis K. McBride, to develop robotic-enabled transcranial magnetic stimulation with D-cycloserine for military and first responder PTSD and depression. The initiative, in partnership with Zeta Surgical’s FDA-cleared AI neuronavigation, aims for mobile, sub-millimeter accuracy TMS devices deployable without specialist clinicians.
1. NRx Defense Systems Established
NRx Pharmaceuticals has formed NRx Defense Systems, a Florida-based R&D subsidiary focused on neuroplastic treatments for depression and PTSD in military and first responder settings. The new unit is headed by Dr. Dennis K. McBride, leveraging his Navy medical and DARPA program management experience to drive defense-focused therapy development.
2. Robotics-Enabled TMS and D-Cycloserine Partnership
The subsidiary will combine oral D-cycloserine (NRX-101) with robotic-enabled transcranial magnetic stimulation under Zeta Surgical’s AI-powered neuronavigation platform, which received FDA 510(k) clearance in October 2025. This collaboration aims to produce compact, mobile systems delivering sub-millimeter targeting accuracy without head fixation or general anesthesia.
3. Strategic Defense Deployment and Funding
NRx Defense Systems plans to pursue non-dilutive government and NGO research partnerships to accelerate forward-deployable TMS solutions, addressing force readiness by enabling rapid PTSD and depression treatment without relying on specialist clinicians. The prototype is slated for unveiling at the Clinical TMS Society’s annual meeting in June 2026.